Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA (2020)
Sequence: cRGD motif + R9 (RRRRRRRRR)
| Experiment Id | EXP002021 |
|---|---|
| Paper | Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA |
| Peptide | cRGD-R9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | rrPPC 10 µg/well (siRNA:rrPPC = 1:10 w/w) |
| Rna Concentration | siRNA 0.2–5 µg/well (assay dependent) |
| Mixing Ratio | siRNA:rrPPC = 1:10 (w/w) |
| Formulation Format | polymeric nanoparticle (rrPPC/siRNA) |
| Formulation Components | PEI1.8K + PEG + cholesterol + cRGD-R9 peptide |
| Size Nm | 195.00 |
| Zeta Mv | 41.90 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | C26 mouse colon carcinoma cells |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown, proliferation, apoptosis |
| Output Value | ≈5-fold STAT3 mRNA reduction; strong growth inhibition; apoptosis induction |
| Output Units | |
| Output Notes | STAT3 silencing confirmed by qPCR and Western blot; clonogenic and apoptosis assays positive |
| Toxicity Notes | Lower cytotoxicity than PEI25K; good in vitro safety |
| Curation Notes |